臨床腫瘍学次世代シーケンシング（NGS）の世界市場2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Clinical Oncology Next Generation Sequencing (NGS) Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D0GIR-00607 • 出版社/出版日：GlobalInfoResearch / 2020年9月18日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、124ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、臨床腫瘍学次世代シーケンシング（NGS）の世界市場を広く調査・分析し、今後の市場展望をまとめております。臨床腫瘍学次世代シーケンシング（NGS）の種類別市場規模（NGSプレシーケンス、シーケンス、NGSデータ分析、一次、二次、三次データ分析）、用途別市場規模（学術・臨床研究、病院・クリニック、製薬・イオテクノロジー企業）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Illumina、Macrogen、Knome、Roche、Oxford Nanopore Technologies、Agilent Technologies、DNASTAR、GATC Biotech、Genomatix Software、Life Technologies、Qiagen、Partek、Exosome Diagnostics、Foundation Medicine、Perkin Elmer、BGI、Biomatters、GnuBIO、Pacific Bioscience、CLC Bio、Paradigm、Caris Life Sciences、Myriad Genetics ・地域別グローバル市場分析 2015年-2020年 ・臨床腫瘍学次世代シーケンシング（NGS）の北米市場（アメリカ、カナダ、メキシコ） ・臨床腫瘍学次世代シーケンシング（NGS）のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・臨床腫瘍学次世代シーケンシング（NGS）のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・臨床腫瘍学次世代シーケンシング（NGS）の南米市場（ブラジル、アルゼンチン） ・臨床腫瘍学次世代シーケンシング（NGS）の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：NGSプレシーケンス、シーケンス、NGSデータ分析、一次、二次、三次データ分析 ・用途別分析：学術・臨床研究、病院・クリニック、製薬・イオテクノロジー企業 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The global Clinical Oncology Next Generation Sequencing (NGS) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 10.1% in the forecast period of 2020 to 2025 and will expected to reach USD 1065.7 million by 2025, from USD 725.1 million in 2019.

The Clinical Oncology Next Generation Sequencing (NGS) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Clinical Oncology Next Generation Sequencing (NGS) market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Clinical Oncology Next Generation Sequencing (NGS) market has been segmented into:
NGS Pre-Sequencing
Sequencing
NGS Data Analysis
Primary, Secondary & Tertiary Data Analysis

By Application, Clinical Oncology Next Generation Sequencing (NGS) has been segmented into:
Academic & Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Clinical Oncology Next Generation Sequencing (NGS) market presented in the report. This section sheds light on the sales growth of different regional and country-level Clinical Oncology Next Generation Sequencing (NGS) markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Clinical Oncology Next Generation Sequencing (NGS) market.

The report offers in-depth assessment of the growth and other aspects of the Clinical Oncology Next Generation Sequencing (NGS) market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Clinical Oncology Next Generation Sequencing (NGS) Market Share Analysis
Clinical Oncology Next Generation Sequencing (NGS) competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Clinical Oncology Next Generation Sequencing (NGS) sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Clinical Oncology Next Generation Sequencing (NGS) sales, revenue and market share for each player covered in this report.

The major players covered in Clinical Oncology Next Generation Sequencing (NGS) are:
Illumina
Macrogen
Knome
Roche
Oxford Nanopore Technologies
Agilent Technologies
DNASTAR
GATC Biotech
Genomatix Software
Life Technologies
Qiagen
Partek
Exosome Diagnostics
Foundation Medicine
Perkin Elmer
BGI
Biomatters
GnuBIO
Pacific Bioscience
CLC Bio
Paradigm
Caris Life Sciences
Myriad Genetics

レポート目次

---

Table of Contents

1 Clinical Oncology Next Generation Sequencing (NGS) Market Overview
1.1 Product Overview and Scope of Clinical Oncology Next Generation Sequencing (NGS)
1.2 Classification of Clinical Oncology Next Generation Sequencing (NGS) by Type
1.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type in 2019
1.2.3 NGS Pre-Sequencing
1.2.4 Sequencing
1.2.5 NGS Data Analysis
1.2.6 Primary, Secondary & Tertiary Data Analysis
1.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market by Application
1.3.1 Overview: Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Academic & Clinical Research
1.3.3 Hospitals & Clinics
1.3.4 Pharma & Biotech Entities
1.4 Global Clinical Oncology Next Generation Sequencing (NGS) Market by Regions
1.4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Clinical Oncology Next Generation Sequencing (NGS) (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Clinical Oncology Next Generation Sequencing (NGS) Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Clinical Oncology Next Generation Sequencing (NGS) Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Clinical Oncology Next Generation Sequencing (NGS) Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Clinical Oncology Next Generation Sequencing (NGS) Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Clinical Oncology Next Generation Sequencing (NGS) Status and Prospect (2015-2025)
2 Company Profiles
2.1 Illumina
2.1.1 Illumina Details
2.1.2 Illumina Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Illumina SWOT Analysis
2.1.4 Illumina Product and Services
2.1.5 Illumina Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.2 Macrogen
2.2.1 Macrogen Details
2.2.2 Macrogen Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Macrogen SWOT Analysis
2.2.4 Macrogen Product and Services
2.2.5 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.3 Knome
2.3.1 Knome Details
2.3.2 Knome Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Knome SWOT Analysis
2.3.4 Knome Product and Services
2.3.5 Knome Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Roche SWOT Analysis
2.4.4 Roche Product and Services
2.4.5 Roche Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.5 Oxford Nanopore Technologies
2.5.1 Oxford Nanopore Technologies Details
2.5.2 Oxford Nanopore Technologies Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Oxford Nanopore Technologies SWOT Analysis
2.5.4 Oxford Nanopore Technologies Product and Services
2.5.5 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.6 Agilent Technologies
2.6.1 Agilent Technologies Details
2.6.2 Agilent Technologies Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Agilent Technologies SWOT Analysis
2.6.4 Agilent Technologies Product and Services
2.6.5 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.7 DNASTAR
2.7.1 DNASTAR Details
2.7.2 DNASTAR Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 DNASTAR SWOT Analysis
2.7.4 DNASTAR Product and Services
2.7.5 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.8 GATC Biotech
2.8.1 GATC Biotech Details
2.8.2 GATC Biotech Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 GATC Biotech SWOT Analysis
2.8.4 GATC Biotech Product and Services
2.8.5 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.9 Genomatix Software
2.9.1 Genomatix Software Details
2.9.2 Genomatix Software Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Genomatix Software SWOT Analysis
2.9.4 Genomatix Software Product and Services
2.9.5 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.10 Life Technologies
2.10.1 Life Technologies Details
2.10.2 Life Technologies Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Life Technologies SWOT Analysis
2.10.4 Life Technologies Product and Services
2.10.5 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.11 Qiagen
2.11.1 Qiagen Details
2.11.2 Qiagen Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Qiagen SWOT Analysis
2.11.4 Qiagen Product and Services
2.11.5 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.12 Partek
2.12.1 Partek Details
2.12.2 Partek Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Partek SWOT Analysis
2.12.4 Partek Product and Services
2.12.5 Partek Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.13 Exosome Diagnostics
2.13.1 Exosome Diagnostics Details
2.13.2 Exosome Diagnostics Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Exosome Diagnostics SWOT Analysis
2.13.4 Exosome Diagnostics Product and Services
2.13.5 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.14 Foundation Medicine
2.14.1 Foundation Medicine Details
2.14.2 Foundation Medicine Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Foundation Medicine SWOT Analysis
2.14.4 Foundation Medicine Product and Services
2.14.5 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.15 Perkin Elmer
2.15.1 Perkin Elmer Details
2.15.2 Perkin Elmer Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Perkin Elmer SWOT Analysis
2.15.4 Perkin Elmer Product and Services
2.15.5 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.16 BGI
2.16.1 BGI Details
2.16.2 BGI Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 BGI SWOT Analysis
2.16.4 BGI Product and Services
2.16.5 BGI Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.17 Biomatters
2.17.1 Biomatters Details
2.17.2 Biomatters Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Biomatters SWOT Analysis
2.17.4 Biomatters Product and Services
2.17.5 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.18 GnuBIO
2.18.1 GnuBIO Details
2.18.2 GnuBIO Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 GnuBIO SWOT Analysis
2.18.4 GnuBIO Product and Services
2.18.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.19 Pacific Bioscience
2.19.1 Pacific Bioscience Details
2.19.2 Pacific Bioscience Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 Pacific Bioscience SWOT Analysis
2.19.4 Pacific Bioscience Product and Services
2.19.5 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.20 CLC Bio
2.20.1 CLC Bio Details
2.20.2 CLC Bio Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 CLC Bio SWOT Analysis
2.20.4 CLC Bio Product and Services
2.20.5 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.21 Paradigm
2.21.1 Paradigm Details
2.21.2 Paradigm Major Business and Total Revenue (Financial Highlights) Analysis
2.21.3 Paradigm SWOT Analysis
2.21.4 Paradigm Product and Services
2.21.5 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.22 Caris Life Sciences
2.22.1 Caris Life Sciences Details
2.22.2 Caris Life Sciences Major Business and Total Revenue (Financial Highlights) Analysis
2.22.3 Caris Life Sciences SWOT Analysis
2.22.4 Caris Life Sciences Product and Services
2.22.5 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
2.23 Myriad Genetics
2.23.1 Myriad Genetics Details
2.23.2 Myriad Genetics Major Business and Total Revenue (Financial Highlights) Analysis
2.23.3 Myriad Genetics SWOT Analysis
2.23.4 Myriad Genetics Product and Services
2.23.5 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Clinical Oncology Next Generation Sequencing (NGS) Players Market Share
3.2.2 Top 10 Clinical Oncology Next Generation Sequencing (NGS) Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Market Share by Regions
4.2 North America Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
4.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
4.5 South America Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
5 North America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries
5.1 North America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries (2015-2020)
5.2 USA Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
5.3 Canada Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
5.4 Mexico Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
6 Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries
6.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries (2015-2020)
6.2 Germany Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
6.3 UK Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
6.4 France Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
6.5 Russia Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
6.6 Italy Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries
7.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries (2015-2020)
7.2 China Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
7.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
7.4 Korea Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
7.5 India Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
8 South America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries
8.1 South America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries (2015-2020)
8.2 Brazil Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
8.3 Argentina Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Clinical Oncology Next Generation Sequencing (NGS) by Countries
9.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries (2015-2020)
9.2 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
9.3 UAE Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
9.4 Egypt Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
9.5 South Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Market Share by Type (2015-2020)
10.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Type (2019-2024)
10.3 NGS Pre-Sequencing Revenue Growth Rate (2015-2025)
10.4 Sequencing Revenue Growth Rate (2015-2025)
10.5 NGS Data Analysis Revenue Growth Rate (2015-2025)
10.6 Primary, Secondary & Tertiary Data Analysis Revenue Growth Rate (2015-2025)
11 Global Clinical Oncology Next Generation Sequencing (NGS) Market Segment by Application
11.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Application (2015-2020)
11.2 Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Application (2019-2024)
11.3 Academic & Clinical Research Revenue Growth (2015-2020)
11.4 Hospitals & Clinics Revenue Growth (2015-2020)
11.5 Pharma & Biotech Entities Revenue Growth (2015-2020)
12 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast (2021-2025)
12.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast (2021-2025)
12.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Regions (2021-2025)
12.3 North America Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2021-2025)
12.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2021-2025)
12.6 South America Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Clinical Oncology Next Generation Sequencing (NGS) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Illumina Corporate Information, Location and Competitors
Table 6. Illumina Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 7. Illumina Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 8. Illumina SWOT Analysis
Table 9. Illumina Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 10. Illumina Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Macrogen Corporate Information, Location and Competitors
Table 12. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 13. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2018-2019)
Table 14. Macrogen SWOT Analysis
Table 15. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 16. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Knome Corporate Information, Location and Competitors
Table 18. Knome Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 19. Knome Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 20. Knome SWOT Analysis
Table 21. Knome Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 22. Knome Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Roche Corporate Information, Location and Competitors
Table 24. Roche Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 25. Roche Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 26. Roche SWOT Analysis
Table 27. Roche Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 28. Roche Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Oxford Nanopore Technologies Corporate Information, Location and Competitors
Table 30. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 31. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 32. Oxford Nanopore Technologies SWOT Analysis
Table 33. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 34. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Agilent Technologies Corporate Information, Location and Competitors
Table 36. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 37. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 38. Agilent Technologies SWOT Analysis
Table 39. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 40. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. DNASTAR Corporate Information, Location and Competitors
Table 42. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 43. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 44. DNASTAR SWOT Analysis
Table 45. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 46. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. GATC Biotech Corporate Information, Location and Competitors
Table 48. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 49. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 50. GATC Biotech SWOT Analysis
Table 51. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 52. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Genomatix Software Corporate Information, Location and Competitors
Table 54. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 55. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 56. Genomatix Software SWOT Analysis
Table 57. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 58. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Life Technologies Corporate Information, Location and Competitors
Table 60. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 61. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 62. Life Technologies SWOT Analysis
Table 63. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 64. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Qiagen Corporate Information, Location and Competitors
Table 66. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 67. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 68. Qiagen SWOT Analysis
Table 69. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 70. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Partek Corporate Information, Location and Competitors
Table 72. Partek Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 73. Partek Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 74. Partek SWOT Analysis
Table 75. Partek Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 76. Partek Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Exosome Diagnostics Corporate Information, Location and Competitors
Table 78. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 79. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 80. Exosome Diagnostics SWOT Analysis
Table 81. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 82. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Foundation Medicine Corporate Information, Location and Competitors
Table 84. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 85. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 86. Foundation Medicine SWOT Analysis
Table 87. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 88. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. Perkin Elmer Corporate Information, Location and Competitors
Table 90. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 91. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 92. Perkin Elmer SWOT Analysis
Table 93. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 94. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 95. BGI Corporate Information, Location and Competitors
Table 96. BGI Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 97. BGI Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 98. BGI SWOT Analysis
Table 99. BGI Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 100. BGI Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 101. Biomatters Corporate Information, Location and Competitors
Table 102. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 103. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 104. Biomatters SWOT Analysis
Table 105. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 106. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 107. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Type and Application
Table 108. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 109. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 110. GnuBIO SWOT Analysis
Table 111. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 112. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 113. Pacific Bioscience Corporate Information, Location and Competitors
Table 114. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 115. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 116. Pacific Bioscience SWOT Analysis
Table 117. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 118. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 119. CLC Bio Corporate Information, Location and Competitors
Table 120. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 121. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 122. CLC Bio SWOT Analysis
Table 123. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 124. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 125. Paradigm Corporate Information, Location and Competitors
Table 126. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 127. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 128. Paradigm SWOT Analysis
Table 129. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 130. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 131. Caris Life Sciences Corporate Information, Location and Competitors
Table 132. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 133. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 134. Caris Life Sciences SWOT Analysis
Table 135. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 136. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 137. Myriad Genetics Corporate Information, Location and Competitors
Table 138. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Major Business
Table 139. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Total Revenue (USD Million) (2017-2018)
Table 140. Myriad Genetics SWOT Analysis
Table 141. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 142. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 143. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Players (2015-2020)
Table 144. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Players (2015-2020)
Table 145. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Regions (2015-2020)
Table 146. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Regions (2015-2020)
Table 147. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries (2015-2020)
Table 148. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Countries (2015-2020)
Table 149. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2015-2020)
Table 150. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2015-2020)
Table 151. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Countries (2015-2020)
Table 152. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Countries (2015-2020)
Table 153. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2015-2020)
Table 154. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Countries (2015-2020)
Table 155. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Type (2015-2020)
Table 156. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Type (2015-2020)
Table 157. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Forecast by Type (2021-2025)
Table 158. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2015-2020)
Table 159. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Application (2015-2020)
Table 160. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Forecast by Application (2021-2025)
Table 161. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Clinical Oncology Next Generation Sequencing (NGS) Picture
Figure 2. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type in 2019
Figure 3. NGS Pre-Sequencing Picture
Figure 4. Sequencing Picture
Figure 5. NGS Data Analysis Picture
Figure 6. Primary, Secondary & Tertiary Data Analysis Picture
Figure 7. Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Application in 2019
Figure 8. Academic & Clinical Research Picture
Figure 9. Hospitals & Clinics Picture
Figure 10. Pharma & Biotech Entities Picture
Figure 11. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million) and Growth Rate (2015-2025)
Figure 12. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Players in 2019
Figure 19. Global Top 5 Players Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share in 2019
Figure 20. Global Top 10 Players Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share in 2019
Figure 21. Key Players Market Share Trend
Figure 22. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 23. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Regions (2015-2020)
Figure 24. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Regions in 2018
Figure 25. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 26. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 27. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 28. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 29. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 30. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Countries (2015-2020)
Figure 31. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Countries in 2019
Figure 32. USA Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 33. Canada Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 34. Mexico Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 35. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Countries (2015-2020)
Figure 36. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Countries in 2019
Figure 37. Germany Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 38. UK Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 39. France Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 40. Russia Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 41. Italy Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Countries (2015-2020)
Figure 43. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Countries in 2019
Figure 44. China Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 45. Japan Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 46. Korea Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 47. India Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 48. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 49. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Countries (2015-2020)
Figure 50. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Countries in 2019
Figure 51. Brazil Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 52. Argentina Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 53. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Countries (2015-2020)
Figure 54. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Countries in 2019
Figure 55. Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 56. UAE Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 57. Egypt Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 58. South Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2015-2020)
Figure 59. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Type (2015-2020)
Figure 60. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Type in 2019
Figure 61. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by Type (2021-2025)
Figure 62. Global NGS Pre-Sequencing Revenue Growth Rate (2015-2020)
Figure 63. Global Sequencing Revenue Growth Rate (2015-2020)
Figure 64. Global NGS Data Analysis Revenue Growth Rate (2015-2020)
Figure 65. Global Primary, Secondary & Tertiary Data Analysis Revenue Growth Rate (2015-2020)
Figure 66. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Application (2015-2020)
Figure 67. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Application in 2019
Figure 68. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by Application (2021-2025)
Figure 69. Global Academic & Clinical Research Revenue Growth Rate (2015-2020)
Figure 70. Global Hospitals & Clinics Revenue Growth Rate (2015-2020)
Figure 71. Global Pharma & Biotech Entities Revenue Growth Rate (2015-2020)
Figure 72. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 73. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 74. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share Forecast by Regions (2021-2025)
Figure 75. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2021-2025)
Figure 76. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2021-2025)
Figure 77. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2021-2025)
Figure 78. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2021-2025)
Figure 79. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Forecast (2021-2025)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel

---